Autoimmune hemolytic anemia associated with a formulation of traditional Chinese medicines

Shen, Youjin

doi:10.2146/ajhp080525

Cited by 4 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AIHA may be primary (idiopathic) or secondary to various diseases, including systemic autoimmune disorders [4-6], malignancies [7], and infections [8, 9]. AIHA can also be induced by certain drugs [10, 11]. This disorder is heterogeneous with respect to the type (warm or cold) of antibodies involved.…”

Section: Introductionmentioning

confidence: 99%

“…The current recommendations for the diagnosis and management of this disorder originate from Western Europe and North America, where the epidemiology of hematologic disorders may be different from that in the Orient. Although a few studies have described the clinical characteristics of AIHA in the Asian populations [11, 16-20], information from Asian regions is still limited. Furthermore, there has been no report on the clinical features or natural history of AIHA in the Korean adults.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical features and outcomes of autoimmune hemolytic anemia: a retrospective analysis of 32 cases

et al. 2011

View full text Add to dashboard Cite

BackgroundThere has been no report on the clinical features or natural history of autoimmune hemolytic anemia (AIHA) in the Korean adult population. This study retrospectively analyzed the clinical characteristics and long-term outcomes of AIHA in the Korean adults.MethodsPatients newly diagnosed with AIHA between January 1994 and December 2010 at Chungnam National University Hospital were enrolled. Patient characteristics at diagnosis, response to treatment, and the natural course of the disease were documented.ResultsThirty-two patients (31 females and 1 male) with a median age of 48 years (range, 17-86) were enrolled. Of these, 21.9% were initially diagnosed with secondary AIHA. Thirteen patients (40.6%) were initially diagnosed with Evans' syndrome. Of the 29 patients who were placed on therapy, 27 (93.1%) showed a partial response or better. Nevertheless, 1 year after initiating treatment, 80% of the patients were still treatment-dependent. During follow-up (median length 14 months; range, 0.5-238), 14 of 25 patients (56.0%) who were initially diagnosed with primary warm antibody AIHA were found to have systemic lupus erythematosus (SLE). Median time to conversion to SLE was 8.0 months (95% CI, 4.3-11.7), and the probabilities of conversion at 12 and 24 months were 63% and 91%, respectively. Younger age (<60 years) and a positive fluorescent anti-nuclear antibody test were associated with a higher probability of SLE conversion (P=0.01 and P<0.001, respectively).ConclusionPrimary AIHA is rare. Regular, vigilant testing for SLE is required in patients initially diagnosed with AIHA.

show abstract